Use of inhaled corticosteroids and the risk of cataracts.
about
Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomesRelation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studiesComparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjectsChronic asthma.Epidemiology and management of common pulmonary diseases in older personsAntileukotriene agents in asthma: the dart that kills the elephant?Montelukast: data from clinical trials in the management of asthma.Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 updateRandomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patientsTreating children with asthma. A review of drug therapies.Recent changes: pulmonary medicine.Fortnightly review: modern drug treatment of chronic asthma.Pharmacotherapy of asthma in children, with special reference to leukotriene receptor antagonists.Epidemiology of age-related cataract.A systematic review of drug induced ocular reactions in diabetes.Inhaled and nasal corticosteroids: safety aspects.Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.Inhaled corticosteroids (ICS) and risk of mycobacterium in patients with chronic respiratory diseases: a meta-analysis.Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.Special challenges in treatment and self-management of older women with asthma.Clinical considerations in the use of inhaled corticosteroids for asthma.Inhaled corticosteroids as first-line therapy for asthma. Why they work--and what the guidelines and evidence suggest.Features of asthma in the elderly.Non-cystic fibrosis bronchiectasis.Review article: the limitations of corticosteroid therapy in Crohn's disease.Safety of inhaled corticosteroids in children.Inhaled corticosteroids and the risk of diabetes among the elderlyThe effect of an inhaled corticosteroid on glucose control in type 2 diabetes.Systemic effects of inhaled corticosteroids: an overview.Inhaled corticosteroids for asthma: common clinical quandaries.Risk factors associated with incident cataracts and cataract surgery in the Age-related Eye Disease Study (AREDS): AREDS report number 32.Withdrawal of inhaled corticosteroids in individuals with COPD--a systematic review and comment on trial methodology.Visual performance in giant cell arteritis (temporal arteritis) after 1 year of therapyEvaluation of retrobulbar blood flow in patients with age-related cataract; color Doppler ultrasonographic findings.Glucocorticoids in the treatment of early and late RATime course of action of two inhaled corticosteroids, fluticasone propionate and budesonide.Five year incidence of cataract surgery: the Blue Mountains Eye Study.LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.The role of budesonide in adults and children with mild-to-moderate persistent asthma.Cataract formation and prevention.
P2860
Q22306079-4899941D-486D-48F9-BA23-DF8BBFBCE694Q24655566-DDD18B6E-23F7-4792-BA77-A60A49984AF3Q28350489-67C46896-9C69-412D-87AD-F7C10136F4A5Q28362642-62C373F1-1EDC-4034-8C67-7EE9993088C5Q28397465-151D32D0-D92E-4874-A0DA-B8CD25E81767Q28769366-ACC8D31F-CFC7-45B8-9D38-EC1CA9C51328Q31448541-5F64D82C-C89D-482F-AB17-2E0DDB70EF24Q33591899-9AC71C04-259B-40D7-83B4-9E80B3B58123Q33627353-658A6D6C-65CF-45C7-8391-312FB7F86958Q33729027-68198B59-4F87-4CDD-8683-034736BCE44EQ33793338-F20A6632-084A-444B-A8FD-ACF7674EAD6DQ33793696-9FDEFC63-FB4B-43D7-B344-66CD7F40977AQ33805187-670A6680-3D45-4F0F-A496-F25092F8E6E0Q33812608-F9276F04-0580-4342-8305-CCD0FF537D8CQ33828301-A13CB0F8-D548-4B84-9FB6-52B564318A12Q33851527-56BF529C-4E0E-44BF-B96E-FA060ECFA1EEQ33976334-EB2225A3-FF23-4918-8312-C885276446E1Q33995219-88E76EFB-9732-4A9E-9784-6A54066E96E1Q34065276-1BACB69C-1C1C-4CE6-B0A9-FEC6599268BBQ34127598-088867EE-EE11-45EE-A20E-4AB8B6F2C199Q34186812-5B6A965E-4B0E-49B6-88C2-6A927795CFA7Q34267148-E4A1932C-AEC7-4D41-8506-5D12DB194493Q34342751-A1E70F9D-DC98-4A6D-9188-82167FC192AFQ34360714-1C771AD8-7541-47B7-AF84-FF347EDBADEFQ34374135-8D3EACAE-1387-4BC7-B6E4-CF6F877D34ABQ34523194-C588EED5-9AC0-4D25-8C9E-98FA0D258034Q34524994-AF7F1E57-0889-4278-8E80-7F3C48576866Q34604971-B67197F2-A31B-4D40-8D74-71A38DE117CBQ35056155-00462B80-EA0B-40E9-B06E-63E1C18C84B4Q35135288-CF5A7235-EFB3-46B2-AC9E-0117E4E78676Q35228091-257FC6D8-6395-4070-9C62-BC184DA30AB8Q35257612-F4DC2F12-5C8C-47E4-83EA-2BDCFAEFE79AQ35310742-5D1CB0FC-42A5-4176-B4E1-A73A648937D4Q35500866-18007CB1-2272-4E9C-AD3F-1DF8FD1376FCQ35552156-4EBAC3D0-FCD0-4052-BD13-40D08B1B3B4CQ35564141-8D967553-03B9-45F0-ACC1-8354308FB787Q35590565-4E4088EC-B535-4B40-8E48-6054A3469237Q35703517-518CDEA1-DEF4-4B6A-9332-603E96FFABD2Q35716906-1F0EB1E9-978C-4BD6-B685-D3733940AB03Q35790808-52B06812-3F61-4196-8ABC-235DBCB7C37B
P2860
Use of inhaled corticosteroids and the risk of cataracts.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Use of inhaled corticosteroids and the risk of cataracts.
@en
Use of inhaled corticosteroids and the risk of cataracts.
@nl
type
label
Use of inhaled corticosteroids and the risk of cataracts.
@en
Use of inhaled corticosteroids and the risk of cataracts.
@nl
prefLabel
Use of inhaled corticosteroids and the risk of cataracts.
@en
Use of inhaled corticosteroids and the risk of cataracts.
@nl
P1476
Use of inhaled corticosteroids and the risk of cataracts
@en
P2093
P356
10.1056/NEJM199707033370102
P407
P577
1997-07-01T00:00:00Z